A detailed history of Charles Schwab Investment Management Inc transactions in Ligand Pharmaceuticals Inc stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 163,924 shares of LGND stock, worth $18.3 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
163,924
Previous 155,340 5.53%
Holding current value
$18.3 Million
Previous $13.1 Million 25.46%
% of portfolio
0.0%
Previous 0.0%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$82.7 - $110.11 $709,896 - $945,184
8,584 Added 5.53%
163,924 $16.4 Million
Q2 2024

Aug 12, 2024

BUY
$68.53 - $87.91 $381,300 - $489,131
5,564 Added 3.71%
155,340 $13.1 Million
Q1 2024

May 08, 2024

SELL
$68.64 - $89.2 $803,362 - $1.04 Million
-11,704 Reduced 7.25%
149,776 $10.9 Million
Q4 2023

Feb 06, 2024

BUY
$49.57 - $72.63 $212,804 - $311,800
4,293 Added 2.73%
161,480 $11.5 Million
Q3 2023

Nov 08, 2023

BUY
$58.86 - $72.67 $162,512 - $200,641
2,761 Added 1.79%
157,187 $9.42 Million
Q2 2023

Aug 09, 2023

BUY
$69.53 - $79.33 $507,082 - $578,553
7,293 Added 4.96%
154,426 $11.1 Million
Q1 2023

May 11, 2023

SELL
$65.67 - $77.08 $1.41 Million - $1.66 Million
-21,493 Reduced 12.75%
147,133 $10.8 Million
Q4 2022

Feb 13, 2023

BUY
$61.72 - $96.74 $496,784 - $778,660
8,049 Added 5.01%
168,626 $11.3 Million
Q3 2022

Nov 14, 2022

BUY
$0.01 - $107.56 $15 - $162,738
1,513 Added 0.95%
160,577 $13.8 Million
Q2 2022

Aug 15, 2022

BUY
$74.52 - $117.06 $341,525 - $536,485
4,583 Added 2.97%
159,064 $14.2 Million
Q1 2022

May 13, 2022

BUY
$94.99 - $151.56 $120,447 - $192,178
1,268 Added 0.83%
154,481 $17.4 Million
Q4 2021

Feb 11, 2022

BUY
$127.69 - $165.85 $1.21 Million - $1.57 Million
9,455 Added 6.58%
153,213 $23.7 Million
Q3 2021

Nov 16, 2021

BUY
$102.33 - $144.73 $673,843 - $953,047
6,585 Added 4.8%
143,758 $20 Million
Q2 2021

Aug 16, 2021

BUY
$113.03 - $155.64 $864,340 - $1.19 Million
7,647 Added 5.9%
137,173 $18 Million
Q1 2021

May 17, 2021

BUY
$99.52 - $215.83 $838,057 - $1.82 Million
8,421 Added 6.95%
129,526 $19.7 Million
Q4 2020

Feb 16, 2021

BUY
$80.55 - $106.05 $63,876 - $84,097
793 Added 0.66%
121,105 $12 Million
Q3 2020

Nov 13, 2020

BUY
$89.56 - $126.72 $1.54 Million - $2.18 Million
17,216 Added 16.7%
120,312 $11.5 Million
Q2 2020

Aug 14, 2020

SELL
$68.28 - $123.65 $67,255 - $121,795
-985 Reduced 0.95%
103,096 $11.5 Million
Q1 2020

May 15, 2020

SELL
$63.37 - $107.88 $372,298 - $633,795
-5,875 Reduced 5.34%
104,081 $7.57 Million
Q4 2019

Feb 07, 2020

SELL
$96.94 - $113.59 $2.96 Million - $3.46 Million
-30,486 Reduced 21.71%
109,956 $11.5 Million
Q3 2019

Nov 08, 2019

SELL
$86.25 - $120.16 $3.34 Million - $4.65 Million
-38,712 Reduced 21.61%
140,442 $14 Million
Q2 2019

Aug 09, 2019

SELL
$107.38 - $129.34 $2.26 Million - $2.72 Million
-21,037 Reduced 10.51%
179,154 $20.5 Million
Q1 2019

May 14, 2019

BUY
$105.93 - $142.47 $1.82 Million - $2.45 Million
17,189 Added 9.39%
200,191 $25.2 Million
Q4 2018

Feb 14, 2019

BUY
$128.36 - $272.13 $1.31 Million - $2.77 Million
10,180 Added 5.89%
183,002 $24.8 Million
Q3 2018

Nov 13, 2018

BUY
$211.18 - $274.49 $7.8 Million - $10.1 Million
36,951 Added 27.2%
172,822 $47.4 Million
Q2 2018

Aug 08, 2018

BUY
$150.77 - $207.98 $234,899 - $324,032
1,558 Added 1.16%
135,871 $28.1 Million
Q1 2018

May 07, 2018

BUY
$138.63 - $182.62 $495,047 - $652,136
3,571 Added 2.73%
134,313 $22.2 Million
Q4 2017

Jan 17, 2018

BUY
$128.36 - $147.04 $378,662 - $433,768
2,950 Added 2.31%
130,742 $17.9 Million
Q3 2017

Nov 13, 2017

BUY
$120.91 - $137.94 $15.5 Million - $17.6 Million
127,792
127,792 $17.4 Million

Others Institutions Holding LGND

About LIGAND PHARMACEUTICALS INC


  • Ticker LGND
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 16,882,800
  • Market Cap $1.88B
  • Description
  • Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19;...
More about LGND
Track This Portfolio

Track Charles Schwab Investment Management Inc Portfolio

Follow Charles Schwab Investment Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Charles Schwab Investment Management Inc with notifications on news.